Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Research analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” ...

Tonix shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results.

Tonix Pharmaceuticals (TNXP) stock jumped 11% Friday after the company issued a business update along with a preliminary 2024 ...

Tonix Pharmaceuticals Holding Corp. * * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...

Tonix Pharmaceuticals (NASDAQ: TNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cas ...

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to ...

CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of ...